<DOC>
	<DOCNO>NCT00515632</DOCNO>
	<brief_summary>Type 2 diabetes mellitus metabolic disorder primarily characterize insulin resistance , relative insulin deficiency , hyperglycemia . People type 2 diabetes high risk many serious diabetic complication , include cardiovascular disease , blindness , nerve damage kidney damage . Balaglitazone thiazolidinedione derivative develop oral anti-diabetic drug improve blood glucose control patient type 2 diabetes . The purpose study assess additional treatment balaglitazone patient type 2 diabetes stable insulin treatment improve blood glucose control decrease daily insulin dose compare placebo , less impact weight gain oedema pioglitazone ( Actos® ) 45 mg .</brief_summary>
	<brief_title>Efficacy Safety Treatment With Balaglitazone Type 2 Diabetes Patients Stable Insulin Therapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>1 . Type 2 diabetes mellitus , diagnose accord 1999 WHO criteria least 3 month 2 . Age ≥ 18 year 3 . BMI ≥ 25.0 kg/m2 4 . HbA1c ≥ 7.0 % 5 . Treatment insulin stable dose least 30 U/day ( ± 4 U/day ) , least 75 day 1 . Prior current use PPARγ agonist 2 . Recent use ( &lt; 3 month ) investigational drug 3 . Preexisting medical condition judge preclude safe participation study 4 . Contraindication/intolerance study medication 5 . Use drug Investigator 's opinion could interfere glucose level ( e.g . systemic corticosteroid ) 6 . Diagnosed receive medication heart failure , NYHA I IV 7 . Hospitalisation major CV event last 3 month , schedule major CV intervention 8 . Uncontrolled treated/untreated systolic blood pressure &gt; 180 mmHg and/or diastolic blood pressure &gt; 95 mmHg 9 . Known diabetic macular oedema 10 . Hematuria 11 . Serum creatinine &gt; 130 μmol/l 12 . ALT , AST , total bilirubin alkaline phosphatase ≥ 2.5 time upper limit normal 13 . Haemoglobin significantly ( Investigators opinion , 1 mmol/L ) low limit normal haemoglobinopathy interfere valid HbA1c assay 14 . Pregnancy , breast feeding planning pregnancy use adequate contraceptive method ( adequate contraceptive measure intrauterine device oral contraceptive ) 15 . Mental incapacity , unwillingness , language barrier preclude adequate understanding cooperation 16 . Abuse alcohol drug , presence condition Investigators opinion may lead poor adherence study protocols 17 . Cancer clinically significant disease disorder , except condition associate type 2 diabetes , Investigator 's opinion could interfere result trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Type 2 diabetes mellitus Stable insulin therapy</keyword>
	<keyword>Balaglitazone</keyword>
	<keyword>Pioglitazone ( Actos® )</keyword>
	<keyword>HbA1c</keyword>
	<keyword>Weight gain</keyword>
	<keyword>Oedema</keyword>
	<keyword>Fasting blood glucose</keyword>
</DOC>